Search / 97680 results found

  • Updated

EDEN PRAIRIE, Minn., Jan. 21, 2021 /PRNewswire/ -- MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, today announced the closing of its Series B funding including $35 million in new money plus the conversion of previously issued convertible notes. The funding was led by a major multinational med-tech company and included participation from new investors Perceptive Advisors, Deerfield Management and Aphelion / Cardeation Capital as well as existing investors including Concord Health Partners. Raymond James & Associates, Inc. acted as sole placement agent for the transaction.

We are there for the homecoming of a local man who was pardoned by President Trump on his last day in office.